No Influence of Age-Related Hearing Loss on Brain Amyloid-β.


Journal

Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863

Informations de publication

Date de publication:
2022
Historique:
pubmed: 23 11 2021
medline: 16 2 2022
entrez: 22 11 2021
Statut: ppublish

Résumé

Hearing loss is independently associated with a faster rate of cognitive decline in older adults and has been identified as a modifiable risk factor for dementia. The mechanism for this association is unknown, and there has been limited exploration of potential casual pathology. Our objective was to investigate whether there was an association between degree of audiometrically measured hearing loss (HL) and brain amyloid-β (Aβ) in a pre-clinical sample. Participants of the Australian Imaging and Biomarker Longitudinal Study (AIBL; n = 143) underwent positron emission tomography (PET) imaging and objective measurement of hearing thresholds within 5 years of imaging, as well as cognitive assessment within 2 years of imaging in this observational cohort study. With one exception, study participants who had cognitive assessments within 2 years of their PET imaging (n = 113) were classified as having normal cognition. There was no association between cognitive scores and degree of hearing loss, or between cognitive scores and Aβ load. No association between HL and Aβ load was found once age was controlled for. As previously reported, positive Apolipoprotein E4 (APOE4) carrier status increased the risk of being Aβ positive (p = 0.002). Degree of HL was not associated with positive Aβ status.

Sections du résumé

BACKGROUND
Hearing loss is independently associated with a faster rate of cognitive decline in older adults and has been identified as a modifiable risk factor for dementia. The mechanism for this association is unknown, and there has been limited exploration of potential casual pathology.
OBJECTIVE
Our objective was to investigate whether there was an association between degree of audiometrically measured hearing loss (HL) and brain amyloid-β (Aβ) in a pre-clinical sample.
METHODS
Participants of the Australian Imaging and Biomarker Longitudinal Study (AIBL; n = 143) underwent positron emission tomography (PET) imaging and objective measurement of hearing thresholds within 5 years of imaging, as well as cognitive assessment within 2 years of imaging in this observational cohort study.
RESULTS
With one exception, study participants who had cognitive assessments within 2 years of their PET imaging (n = 113) were classified as having normal cognition. There was no association between cognitive scores and degree of hearing loss, or between cognitive scores and Aβ load. No association between HL and Aβ load was found once age was controlled for. As previously reported, positive Apolipoprotein E4 (APOE4) carrier status increased the risk of being Aβ positive (p = 0.002).
CONCLUSION
Degree of HL was not associated with positive Aβ status.

Identifiants

pubmed: 34806606
pii: JAD215121
doi: 10.3233/JAD-215121
pmc: PMC8842788
doi:

Substances chimiques

Amyloid beta-Peptides 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

359-367

Références

Clin J Sport Med. 2003 Jan;13(1):28-32
pubmed: 12544161
Neurobiol Aging. 2015 Jan;36 Suppl 1:S159-66
pubmed: 25257985
Science. 2002 Jul 19;297(5580):353-6
pubmed: 12130773
Am J Epidemiol. 1998 Nov 1;148(9):879-86
pubmed: 9801018
Neuroimage. 2014 Apr 15;90:84-92
pubmed: 24412398
JAMA Otolaryngol Head Neck Surg. 2018 Feb 1;144(2):115-126
pubmed: 29222544
Lancet. 2017 Dec 16;390(10113):2673-2734
pubmed: 28735855
Front Neurol. 2019 Apr 24;10:391
pubmed: 31105633
J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):870-881
pubmed: 30967444
Am J Alzheimers Dis Other Demen. 2020 Jan-Dec;35:1533317519871167
pubmed: 31510756
Brain. 2021 Mar 3;144(2):391-401
pubmed: 33351095
Eur J Epidemiol. 2019 Feb;34(2):125-130
pubmed: 30306425
Alzheimers Dement. 2021 Jul 21;:
pubmed: 34288382
Alzheimers Dement. 2020 Mar 10;:
pubmed: 32157811
BMC Psychol. 2013 Dec 23;1(1):30
pubmed: 25566378
Semin Hear. 2015 Aug;36(3):140-9
pubmed: 27516714
Alzheimers Dement (Amst). 2020 Sep 25;12(1):e12108
pubmed: 33005726
J Alzheimers Dis. 2013;33(3):675-9
pubmed: 23001710
Neurology. 2021 Feb 2;96(5):e662-e670
pubmed: 33184233
Neuron. 2020 Nov 11;108(3):401-412
pubmed: 32871106
Alzheimers Dement. 2015 Jan;11(1):1-15.e1-4
pubmed: 25443857
Comput Med Imaging Graph. 2018 Nov;69:43-51
pubmed: 30172092
Neurobiol Aging. 2010 Aug;31(8):1275-83
pubmed: 20472326
Aging (Albany NY). 2019 May 22;11(10):3156-3169
pubmed: 31118310
Neurology. 1993 Apr;43(4):779-85
pubmed: 8469340
Curr Opin Otolaryngol Head Neck Surg. 2017 Oct;25(5):347-352
pubmed: 28661962
Neurology. 2013 Apr 2;80(14):1341-8
pubmed: 23547267
J Neurosci. 2011 Aug 31;31(35):12638-43
pubmed: 21880924
JAMA Otolaryngol Head Neck Surg. 2020 Nov 1;146(11):1035-1042
pubmed: 32880621
J Alzheimers Dis Rep. 2021 Jun 03;5(1):443-468
pubmed: 34368630
Nat Neurosci. 2020 Oct;23(10):1183-1193
pubmed: 32778792
Clin Otolaryngol. 2016 Dec;41(6):718-729
pubmed: 26670203
Lancet. 2020 Aug 8;396(10248):413-446
pubmed: 32738937
J Alzheimers Dis. 2018;64(s1):S633-S646
pubmed: 29782318
Lancet Neurol. 2016 Sep;15(10):1044-53
pubmed: 27450471
Cogn Behav Neurol. 2016 Jun;29(2):68-77
pubmed: 27336804
Neuroimage. 2018 Dec;183:387-393
pubmed: 30130643
Ageing Res Rev. 2015 Sep;23(Pt B):154-66
pubmed: 26123097
Otol Neurotol. 2019 Oct;40(9):e883-e893
pubmed: 31498297
Nat Neurosci. 2019 Jan;22(1):57-64
pubmed: 30559471
J Neurol Neurosurg Psychiatry. 2020 Feb;91(2):172-176
pubmed: 31699832
J Clin Exp Neuropsychol. 2006 Oct;28(7):1095-112
pubmed: 16840238
J Clin Exp Neuropsychol. 2012;34(4):345-58
pubmed: 22248010
Eur Arch Otorhinolaryngol. 2011 Aug;268(8):1101-1107
pubmed: 21499871
Laryngoscope. 2021 Mar;131(3):633-638
pubmed: 32644260
Alzheimers Dement (Amst). 2019 Feb 28;11:205-215
pubmed: 30859120
JAMA Netw Open. 2019 Jul 3;2(7):e198112
pubmed: 31365110
Cereb Cortex. 2014 Jun;24(6):1609-18
pubmed: 23389995
Arch Clin Neuropsychol. 2009 Mar;24(2):165-78
pubmed: 19395350

Auteurs

Julia Z Sarant (JZ)

The University of Melbourne, Melbourne, Australia.

David C Harris (DC)

The University of Melbourne, Melbourne, Australia.

Peter A Busby (PA)

The University of Melbourne, Melbourne, Australia.

Christopher Fowler (C)

The Florey Institute, Melbourne, Australia.

Jurgen Fripp (J)

Commonwealth Scientific and Industrial Research Organization, Queensland, Australia.

Colin L Masters (CL)

The Florey Institute, Melbourne, Australia.

Paul Maruff (P)

Cogstate, Melbourne, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH